Tag: SIP

As forecast earlier in the year pharmacy wholesaler Sigma Healthcare has omitted interim dividend after reporting reasonably solid results for the six months to July.

A decisive thumbs down from investors for the interim result from Sigma Healthcare’s which revealed profit plunged more than 80% to just $2.52 million.

Sigma Pharmaceuticals continued to make headway in its recovery from the near death experience in 2010.

Life after the near death experience in 2010 for Sigma Pharmaceuticals as the company reported another 12 month heap of red ink, but the shares rose.

Shares in Sigma Pharmaceuticals plummeted 18% and more yesterday after the company shocked the market by revealing it could lose up to 15% of its wholesaling revenue because of a change in strategy by a key supplier.

The move by struggling Sigma Pharmaceuticals to sell its main generic drugs business to Aspen Pharmacare of South Africa may have hit a competition roadblock.

Shares in Sigma Pharmaceuticals eased yesterday after the company revealed, as expected, a big loss for the first half of its 2010-11 financial year.

The chances of Sigma Pharmaceuticals getting a workable takeover offer from South Africa’s Aspen Pharmacare seem to be receding.

As many in the market suspected, Sigma Pharmaceuticals’ putative South African suitor has tried a bit of cheese paring by slicing its proposed 60c a share offer 5c (or 8.25%) to 55c.

Struggling generic drug maker and distributor, Sigma Pharmaceuticals, has found a new CEO to lead the company while it waits to see if it will receive a bid from South African group, Aspen Pharmacare.

Africa’s biggest generics drugs group has been revealed as the bidder for the struggling local group, Sigma Pharmaceuticals.

Sigma Pharmaceuticals has defended the timing of its release of its 2009-10 financial report and its $389 million of losses which triggered a 48% slide in the share price on March 31.

Even after all the warnings, the 2009-10 result from Sigma Pharmaceuticals yesterday was still a surprise, and shocking.

Still no definite news about what’s going on at Sigma Pharmaceuticals.

In a year’s time Sigma Pharmaceuticals reckons it will earn less than it did in 2006-07, not the greatest of forecasts to be making for any company.

Drug manufacturer and distributor, Sigma Pharmaceuticals (SIP) has met its annual earnings forecast and said net profit would rise 7% this year, propelling its shares up 5%.

The market yesterday administered one of the biggest hidings seen for some time to a leading industrial stock when it sold down the shares of Sigma Pharmaceuticals by 20 per cent after a surprise profit downgrade.

Australia’s biggest pharmaceuticals group, Sigma, has struck some first quarter earnings problems.